(Click to Watch Video) –
by University of Miami Leonard M. Miller School of Medicine – Medical Xpress –
A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.
While the study doesn’t answer the question of whether cell therapy in remission is the right choice, it does say that it’s not the wrong choice.
